Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia
FOLFOX plus nab-paclitaxel exceeds expected ORR, shows favourable haematotoxicity in gastric/GEJ adenocarcinoma
20 Dec 2024
bởiNatalia Reoutova
An open-label single-arm phase II trial of FOLFOX and nab-paclitaxel (FOLFOX-A) reports a target-exceeding objective response rate (ORR) and a more favourable haematologic toxicity profile than triplet regimen historical controls in metastatic/advanced unresectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
FOLFOX plus nab-paclitaxel exceeds expected ORR, shows favourable haematotoxicity in gastric/GEJ adenocarcinoma
20 Dec 2024
CameL at 5 years: 1L camrelizumab plus chemo maintains long-term OS benefit
19 Dec 2024
bởiNatalia Reoutova
The 5-year update of the phase III CameL study of camrelizumab plus carboplatin and pemetrexed (C+CP) in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations demonstrates continued overall survival (OS) and progression-free survival (PFS) benefits.